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Primary sensitization  in vivo results in an increase in the number of antigen- 
reactive  effector T  cells and  an  augmented  cell-mediated  response.  Repeated 
immunization  can  further  increase  the  number  of antigen-reactive  effector T 
cells, but eventually a plateau of responsiveness is reached; mediated in part by 
a complex network of specific and nonspecific regulatory systems that limit the 
clonal expansion of antigen-reactive T cells. By selectively expanding the number 
of antigen-reactive T  cells in vitro and then adoptively transferring such cultured 
T  cells into  the  host,  it  has become possible to augment  in vivo cell-mediated 
immunity to a variety of viral (1, 2), tumor (3-8), transplantation  (10), and tissue 
antigens  (1 1,  12), and to potentially achieve a  higher degree of responsiveness 
than can be generated by active in vivo immunization. 
Immune  T  cell  lines  for  use  in  vivo  have  been  grown  in  vitro  using  two 
overlapping but distinct approaches that allow for the derivation of IL-2-depend- 
ent or antigen-driven  T  cell lines (reviewed in  13).  IL-2-dependent T  cell lines 
can  be  generated  by activating  T  cells  to  express  IL-2  receptors  by specific 
antigen  stimulation,  then  inducing  proliferation  of antigen-activated  T  cells by 
repeated  supplementation  of the  culture  media  with  IL-2  (i.e.,  after  antigen 
activation, exogenous IL-2 serves as the major stimulus for proliferation). Alter- 
natively,  antigen-driven  T  cell  lines can  be generated  by intermittent  specific 
stimulation of immune T  cells with antigen on filler cells without the addition of 
exogenous IL-2 (i.e., antigen is the major stimulus for proliferation, and presum- 
ably acts by inducing  production  of endogenous  IL-2).  The  filler cells,  usually 
irradiated  syngeneic spleen cells, perform several potential functions, including 
antigen processing, antigen presentation, and secretion of growth and/or differ- 
entiation factors. 
To determine  the  feasibility of using cultured T  cells as reagents  in vivo to 
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augment specific T  cell immunity,  we have extensively examined the immuno- 
biology of cultured T  cells in models for the adoptive tumor therapy of antigenic 
murine leukemia.  Previous studies (5) examined IL-2-dependent T  cell lines in 
vivo and showed that T  cells specifically cytotoxic to murine leukemia could be 
greatly expanded in number by culture with IL-2, and could be used for specific 
adoptive tumor therapy. However, such T  cell lines were exquisitely dependent 
upon exogenous IL-2, and died rapidly in vitro or in vivo (14) without repeated 
supplementation  with IL-2. Thus,  these transferred cells were functionally lim- 
ited in vivo without frequent administration  of exogenous IL-2 (15). Moreover, 
the  demonstrated  inability  of IL-2-dependent  long  term-cultured  T  cells  to 
survive in  vivo implied  that  such T  cells would be inappropriate  reagents  for 
providing immunologic memory in vivo. 
To overcome the problems of rapid donor T  cell death in vivo and the inability 
of IL-2-dependent  long  term-cultured  T  cell  lines  to  provide  immunologic 
memory  in  vivo,  we  have  developed  and  studied  antigen-driven  long-term 
cultured  T  cell  lines.  Antigen-driven  T  cell  lines derived from  B6  mice were 
generated reactive to FBL-3, a  syngeneic Friend virus-induced leukemia.  Such 
cultured T  cells were greatly expanded in number and specifically cytotoxic to 
FBL-3 tumor. However, in distinction to IL-2-dependent T cell lines, the antigen- 
driven T  cell lines produced IL-2 and proliferated in vitro in response to specific 
stimulation by irradiated  FBL-3. Moreover, these T  cells could rest in vitro for 
>1  mo  on  syngeneic  filler  cells  without  antigen  stimulation  and  retain  the 
capability  of subsequently  responding  specifically  to  antigen;  they  therefore 
provided an in vitro equivalent of T  cell memory. 
In the current study, antigen-driven  long term-cultured T  cells were used in 
vivo as an adjunct to cyclophosphamide (CY) ~ for the therapy of disseminated 
FBL-3  leukemia  in  a  model  termed  adoptive chemoimmunotherapy  (16,  17). 
The results showed that  tumor-specific, antigen-driven,  long term-cultured  T 
cells could proliferate rapidly in vivo, distribute widely, eradicate disseminated 
FBL-3  leukemia,  survive  long-term  in  vivo and  provide  specific immunologic 
memory long after adoptive transfer. 
Materials and Methods 
Mice.  6-8  wk-old  C57BL/6  mice,  denoted  B6,  were obtained  from  The Jackson 
Laboratory, Bar Harbor, ME. Breeding pairs of B6.PL(74NS)  mice, established congenic 
to C57BL/6 mice for Thy-1  antigen and denoted as B6/Thy-1.1, were obtained from 
The Jackson Laboratory and were maintained  in our colony. 
Tumor.  FBL-3 is a transplanted  Friend virus-induced erythroleukemia of B6 origin 
that possesses tumor-associated surface antigens  that crossreact with other FMR tumors 
(16). 
Generation  of Antigen-driven,  Tumor-specific,  Long  Term-cultured  T  Cells.  Antigen- 
driven long term-cultured T  cells were derived from splenic T  cells of mice immune to 
FBL-3. Donor mice were sensitized to FBL-3 in vivo by innoculation  of 2 ×  107 irradiated 
FBL-3 cells i.p., and immune cells were obtained 4-6 wk later (18). 
T  cells were grown under conditions adopted from those described by Kimoto and 
Fathman (19). 4 X 107 lymphocytes from spleens of mice previously immunized to FBL- 
3 were specifically stimulated by culture for 12 d with 2 x  106 irradiated (12,000 rad 3' 
radiation)  FBL-3 tumor cells in 20 ml of RPMI 1640 media supplemented with 10% FCS, 
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2-ME,  HEPES buffer,  L-glutamine,  and  antibiotics on 8  x  107  irradiated  (3,300  rad  3" 
radiation) B6 spleen cells as filler cells.  On day 12, cells were harvested and viability was 
determined using the vital stain fluorescein diacetate. 
2 x  10  "~ viable recovered T  cells were restimulated  with  10  "~ irradiated  FBL-3 on 5 x 
l0  ~ irradiated filler cells in 2 ml media supplemented with 50% culture supernatant fluid 
from  secondary  mixed  leukocyte cultures  as  described  by Glasebrook  and  Fitch  (20), 
denoted MLC-SF. Following a reculture period of 10-12 d, the expanded cells were again 
restimulated under similar conditions but with the addition of 10% MLC-SF to the media. 
The MLC-SF contained ~2-4 U of IL-2 per milliliter, and was used to circumvent culture 
crisis.  No MLC-SF was added in subsequent restimulations,  which were performed every 
10-12 d. After 62 d of culture, the resultant T  cells, expanded ~ 1,000-fold, were tested 
in vitro to confirm specific proliferative and cytolytic function, and tested in vivo in tumor 
therapy. 
Interleukin  2.  Specific activity of IL-2 was determined in vitro in a standard functional 
microassay measuring the capacity of IL-2 to induce the replication of an IL-2-dependent 
T  cell line,  as quantified by thymidine incorporation (21). The units of specific activity 
were adjusted to correspond to the activity of an IL-2 reference standard provided by the 
Biological Resources Branch of the Biological Response Modifiers Program of the National 
Cancer Institute. 
Purified human recombinant IL-2 was provided by the Immunex Corp., Seattle, WA, 
and  Hoffman-LaRoche,  Inc.,  Nutley,  NJ.  The  dose  used  in  vivo,  2.4  x  l03  U/d  (U 
corresponding to the Reference Standard and equivalent to 80 U  of functional activity in 
several of our previous publications [14,  15]), was previously shown to induce the in vivo 
proliferation (l 4, 22) and augment the function of tumor-specific IL-2-dependent T  cells 
(l 5). This dose of IL-2 was below the level required to induce lymphokine-activated killer 
(LAK) cells in vivo (23), and in multiple  previous experiments  was shown to induce no 
detectable antitumor effect when used alone or as an adjunct to CY (15). 
Model to Count Donor T Cells In Vivo.  To identify and quantify donor T  cells in vivo, 
mice congenic at the Thy-1  locus were used for therapy (14,  17, 22). Thus, B6/Thy-l.1 
host mice  were  inoculated  i.p.  with  long term-cultured  T  cells  derived  from B6 mice 
(which  are  Thy-l.2).  Proliferation,  distribution,  and  persistence  of donor  T  cells  was 
determined by enumeration  of donor Thy-l.2 + cells in host ascites,  spleen,  and  mesen- 
teric  and  axillary  lymph  nodes  at  subsequent  time  points.  T  cells  were  labeled  with 
fluorescein-conjugated monoclonal anti-Thy-l.2  (Becton-Dickinson Monoclonai Center, 
Sunnyvale, CA) for counting by phase/fluorescence microscopy as previously detailed (14, 
22).  B6 mice are  low responders  to Thy antigens  (24), and previous studies  (17) have 
shown  that  no  immune  response  to  disparities  at  the  Thy-1  allele  is  generated  after 
adoptive transfer of donor T  cells into congenic hosts, and that the trarfsfer of specific T 
cell immunity from donor to host is equally effective regardless of whether the donor of 
immune T  cells is syngeneic or congenic. 
Therapy Model; Adoptive Chemoiramunotherapy.  This assay, previously described in detail 
(5,  15-17),  consists of treating  mice bearing  established  disseminated  FBL-3  leukemia 
with a combination of chemotherapy and adoptively transferred immune cells. On day 0, 
host mice are inoculated i.p. with 5 x  10  .6 viable FBL-3 leukemia cells.  By day 5 the tumor 
is disseminated  and mice are treated  with CY at dose of 180 mg/kg followed in 5  h  by 
adoptively transferred  donor cells.  Without therapy,  mice die of disseminated  leukemia 
in ~2  wk. CY reduces the tumor burden and potentially ablates host suppressor T  cells 
(9) and prolongs survival to ~4 wk. Therapy with immune cells alone on day 5  without 
CY has no detectable effect on survival.  However, treatment with CY plus cells immune 
to FBL-3 prolongs survival and cures mice in a cell dose-dependent manner, with larger 
doses of immune cells inducing longer survival and a  greater percentage of cures.  For 
maximum efficacy, donor T cells must be capable of proliferating and surviving long term 
in the host (17, 25). 
To be effective, the donor cell population must contain T  cells specifically immune to 
FBL-3 tumor-associated antigens (i.e., populations of cells from immune donors depleted 
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allogeneic  tumors) (5,  16). In addition,  immune effector T  cells are restricted by gene 
products of the MHC (18). 
Results 
Generation  of Antigen-driven  Long  Term-Cultured  T  Cell  Lines.  Cultured  T 
cells specifically reactive to FBL-3 leukemia were derived from cultures of spleen 
cells  obtained  from  B6  mice  immunized  in  vivo  with  FBL-3  and  induced  to 
proliferate  in  vitro by intermittent  stimulation  with irradiated  FBL-3 on filler 
cells. By the time of therapy on day 62 of culture, the donor T cells had expanded 
in number ~l,000-fold.  Phenotypically, the cultured T  cells were 40-50%  Lyt- 
2 + and 50-60% L3T4 + with no apparent overlapping populations. Functionally, 
the T  cells were able to proliferate in vitro in response to irradiated  FBL-3 on 
syngeneic filler cells, but failed to proliferate on either  syngeneic or allogeneic 
filler cells alone. When stimulated with irradiated FBL-3 on syngeneic filler cells, 
IL-2  was produced and  could be measured  in  culture supernatants  at  36 h  of 
culture at a level of ~2-4 U of IL-2. 
In addition to expressing proliferative function, the T cell lines were specifically 
cytotoxic  to  FBL-3  in  a  standard  4-h  chromium-release  assay  as  previously 
described (.5) for  IL-2-dependent  T  cell lines.  Specificity controls for cytolytic 
reactivity included syngeneic and allogeneic Con A-induced  lymphoblasts and 
EL-4, an antigenically irrelevant syngeneic tumor in experiments similar to those 
described in Table III (data not presented). 
Antigen-driven  Long  Term-cultured  T  Cells  Proliferate  Rapidly  In  Vivo  and 
Distribute  Widely.  B6/Thy-l.1  mice were injected with  5  x  106 viable  FBL-3 
cells on day 0, and on day 5, when tumor was disseminated,  were treated with 
180 mg/kg CY plus 3.3 x  10  6 cultured T  cells derived from B6 mice (i.e.  Thy- 
1.2). On day 11  (i.e.  6 d after cell transfer) donor T  cells in host ascites, spleen, 
and mesenteric lymph nodes were identified by use of fluoresceinated antibody 
to  Thy-l.2.  The  results  (Fig.  1)  showed that  donor  T  cells had  expanded  in 
number in vivo approximately threefold, and comprised 24% of total ascitic cells, 
4%  of spleen  cells,  6%  of mesenteric  lymph  node  cells,  and  0.9%  of axillary 
lymph node cells. 
Injection  of mice  daily with  2.4  x  l0 s  U  of IL-2  i.p.  greatly  increased  the 
already rapid rate of donor T  cell growth (Fig.  1).  By day 6  in vivo, IL-2 had 
increased the total number of donor T  cells approximately eightfold, to 27% of 
total ascitic cells,  12% of spleen cells, 50% of mesenteric lymph node cells, and 
3.8% of axillary lymph node cells. 
Cultured T Cells Are Effective in Tumor Therapy.  Cohorts of the above-treated 
mice  were  followed for  survival  (Fig.  2).  Mice  receiving  no  treatment  had  a 
median survival time of 12 d, and all died by day 13. Therapy on day 5 with CY 
alone  prolonged  the  median  survival  time  to  day  24,  but  all  mice  died.  By 
contrast, therapy on day 5 with CY plus 3.3 ×  106 or 4.0 X  10  7 cultured T  cells 
alone or followed by 2.4  ×  l0 s  U  of IL-2 daily for 6  d  cured  100%  of mice. 
Thus,  as  an  adjunct  to  CY,  even  a  small  dose  of tumor-specific  long  term- 
cultured T  cells were curative in tumor therapy. 
Cultured  T  Cells Persist Long  Term  In  Vivo  in  Cured Mice.  The  cured  mice 
were killed  120 d  after cell transfer and examined for donor T  ceils (Table I). 1104  CULTURED  T  CELLS  PROVIDE  IMMUNOLOGIC  MEMORY  IN  VIVO 
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FIGURE  1.  Antigen-driven long term-cultured T  cells proliferate and distribute widely in 
vivo. On  day 0,  B6/Thy-l.1  host mice were injected i.p. with 5  x  10  s viable FBL-3 tumor 
cells. On day 5, when tumor was disseminated, mice were treated with adoptive chemoimmu- 
notherapy using CY (180 mg/kg) plus 3.3 X  106 B6 (i.e.  Thy-l.2) antigen-driven long term- 
cultured T  cells alone or followed by IL-2 injected i.p. daily at a  dose of 2.5  x  10  ~ U/day. 
The long term-cultured T  cells were specifically immune to FBL-3 and were generated by 
culture for 62 d  with proliferation induced by intermittent stimulation with FBL-3.  On day 
I l  of therapy (i.e.  day  6  after cell  transfer) donor T  cells within host ascites,  spleen, and 
mesenteric lymph nodes were identified with fluoresceinated antibody to Thy-1.2 and counted 
by phase/fluorescence microscopy. The data points represent the means of six mice from three 
experiments. 
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FIGURE  2.  Therapy of disseminated FBL-3 leukemia with antigen-driven long term-cultured 
T  cells. On day 0, B6/Tby-1.1  hosts were inoculated i.p. with 5 X 106 viable FBL-3 leukemia 
cells and left untreated, treated on day 5 with  180 mg/kg CY, or treated on day 5  with CY 
plus 3.3 x  106, or 4.0 x  107 antigen-driven long term-cultured T  cells immune to FBL-3 (day 
62 of culture) either alone (six mice) or followed by 2.5 x  103 U of IL-2 daily i.p. for 6 d (six 
mice). The numbers represent surviving mice per total. CHEEVER  ET  AL. 
TABLE  I 
Enumeration of Donor T Cells Persisting  120 d In Vivo in Cured Mice 
1105 
Percent of donor T cells in host lymphoid 
organs* 
Treatment of 
hosts*  Lymph nodes 
Total recoverable donor T 
cells  0 
Ascites  Spleen  Percent of 
Mesenteric  Axillary  Total number  input 
No 1L-2  0.40  0.59  0.93  0.27  0.96 × 108  2.4 
IL-2  1.10  7.19  5.37  1.69  17.60 X 10  n  44.0 
B6]Thy-1.1 mice were inoculated with 5 x  106 viable FBL-3 cells i.p. on day 0 and treated on day 
5 with CY + 4.0 x  107 FBL-specific antigen-driven  long term-cultured T cells (grown to day 62 
in vitro) alone or followed by IL-2. 
* After adoptive tumor therapy, mice received either no exogenous IL-2 or received IL-2 at a dose 
of 2.4 x  103 U i.p. daily for 6 d. 
* On day  125, mice were killed and host lymphoid organs  were examined  for the presence and 
phenotype (Table If) of donor T cells. The number of donor T cells is expressed as a percent of 
total cells in host lymphoid organs, and as an absolute number of donor T cells recoverable in the 
host lymphoid organs examined. 
The total number of donor T cells recoverable is presented as a percent of the number of T cells 
used for therapy on day 5 (i.e., 4.0 x  107 cultured T cells). The data represent the means of two 
experiments. 
In  mice  treated  with  4.0  X  107  donor  T  cells  without  IL-2,  donor  T  cells 
comprised 0.6% of total spleen cells and 0.99%  of total mesenteric lymph node 
cells.  Treatment  with  IL-2 for 5  d  after cell transfer increased the  recoverable 
donor T  cells to 7% of total spleen cells and 5% of total mesenteric lymph node 
cells.  The  total number of recoverable donor  T  cells was 2.4%  of the  original 
number injected in mice not receiving IL-2 and 44% in mice receiving IL-2. As 
previously reported  (17)  for  therapy  with  noncuhured  immune cells,  the  total 
number of nucleated cells and the percentage of T  cells (i.e. donor plus host) in 
lymphoid  organs  of  cured  mice  were  equivalent  to  normal  mice  (data  not 
presented). 
Cultured  Lyt-2  ÷ T  Cells  and L3T4  + T  Cells Survive  Equivalently In  Vivo.  On 
the  day of cell transfer,  ~53%  of cultured  donor T  cells were  Lyt-2  +,  and  the 
remaining donor T  cells were L3T4 +.  Examination of the phenotype of donor 
T  cells recoverable after  120 d  in vivo revealed (Table II) that both Lyt-2  + and 
L3T4 ÷  cultured  T  cells  survived  long  term  in  vivo,  both  were  present  in  all 
lymphoid organs examined, and  both survived in approximately the  same pro- 
portion.  However,  there  was a  moderate  preference  for  survival of L3T4 + T 
cells  in  ascites,  and  for  Lyt-2  +  T  cells  in  spleen  and  lymph  nodes.  Although 
injection  of exogenous  IL-2  after  cell  transfer  greatly  increased  numbers  of 
donor T  cells surviving  120 d  (Table  I), IL-2 did not appreciably influence the 
phenotype of persisting donor  T  cells (Table  II). Concurrent  counts of host T 
cells revealed that  10%  of host T  cells in  spleen and  7-13%  of host T  cells in 
lymph  nodes  were  Lyt-2  +  (Table  II).  Thus,  the  phenotype  of host  T  ceils  in 
treated mice was equivalent to that of normal mice. 
Cultured T Cells Provide Immunologic Memory In Vivo.  Donor T  cells surviving 
120  d  in  vivo were  tested  for persistence of specific proliferative and  cytolytic 
function.  To  assess  proliferative  function,  spleen  cells  from  cured  mice  were 1106  CULTURED  T  CELLS  PROVIDE  IMMUNOLOGIC  MEMORY  IN  VIVO 
TABLE II 
Phenotype of Donor T Cells Persisting 120 d In Vivo in Cured Mice 
Lyt-2  + T  cells (%)* 
Source tissue  Donor  Host 
No IL-2  1L-2  No IL-2  IL-2 
Ascites  44  46  30  23 
Spleen  68  74  10  8 
Mesenteric lymph node  75  75  13  12 
Axillary lymph node  66  66  7  6 
See Table I for details of therapy, 
* The number of donor Lyt-2  ÷ T  cells is expressed as a  percent of total 
donor T  cells, and the number of host Lyt-2  ÷ T  cells is expressed as a 
percent of total host T  cells. 
placed  into  culture  and  stimulated  for  5  d  with  irradiated  FBL-3  or  with 
irradiated  syngeneic  B6  spleen  cells,  and  the  growth  of donor  T  cells  was 
determined  by counting donor T  cells using fluorescence-tagged mAb against 
Thy-1.2. The results showed that donor T cells in spleens of cured mice increased 
18-25%  when  stimulated  by  FBL-3,  and  decreased  43-81%  when  cultured 
without  FBL-3.  Both  donor  L3T4 +  T  cells  and  Lyt-2  +  T  cells  proliferated 
equivalently. 
To  assess  cytolytic  function,  spleen  cells  from  cured  mice  were  similarly 
cultured but tested for ability of such antigen-stimulated cells to mediate specific 
cytolytic reactivity in a standard 4-h chromium-release assay. The results showed 
that  spleen cells from cured mice became specifically cytotoxic to FBL-3 after 
stimulation by FBL-3 (Table III), and that cytotoxicity was mediated by persistent 
donor T  cells (i.e.  Thy-l.2 ÷) as opposed to host T  cells (i.e.  Thy-l.l+). 
Discussion 
One major question concerning the use of cultured T  cells in vivo to augment 
specific T  cell  immunity  was whether such  T  cells could survive and  function 
long term  in vivo (7,  14,  35). Culture conditions for generating antigen-driven 
T  cells, as described previously (13,  19, 20), allow for the generation in vitro of 
immune T  cells that can rest in vitro on syngeneic filler cells (38), and therefore 
may represent an in vitro functional equivalent of memory T  cells. The current 
study extended  these  in  vitro findings  and  showed that  tumor-specific T  cells 
cultured in vitro for 62 d and greatly expanded in number could proliferate in 
vivo, distribute widely to host lymphoid organs, mediate specific tumor therapy, 
and persist long term in vivo as functioning memory T  cells. 
The immune spleen cells for therapy were activated to express IL-2 receptors 
by culture with irradiated  FBL-3, then induced to proliferate and to grow long 
term in vitro by intermittent antigen stimulation every 10-12 d. The T  cell lines 
generated  under  such conditions contained  Lyt-2  ÷ T  cells and  L3T4 + T  cells, 
were specifically cytotoxic to FBL-3, and were able to secrete IL-2 and proliferate 
in vitro in response to antigen-stimulation.  It is likely that different T  cell subsets 
were responsible for mediating cytotoxicity and for producing IL-2, as previously 
reported (26) for similar alloreactive T  cell lines generated under similar condi- CHEEVER  ET  AL.  1107 
TABLE  III 
Antigen-driven  Long Term-cultured T Cells Become Spec~cally  Cytotoxic In Vitro in Response 
to Antigen after  120 d In Vivo 
Percent chromium 
Stimulator  Depletion of donor  release (E/T ratio 
Responder  cells*  or host T cells after  of 20:1)| 
culture* 
FBL  B6  EL-4 
Spleen cells from mice cured with cul-  B6 
tured T cells  FBL 
--  14  1  4 
--  63  -2  1 
Anti-Thy-l.2 + C'  10  --  -- 
Anti-Thy-l.1 + C'  67  --  -- 
Spleen ceils from mice cured with cul-  B6 
tured T cells plus IL-2  FBL 
30  5  4 
55  0  1 
Spleen cells from B6 mice immunized  B6 
with irradiated  FBL cells  FBL 
9  -5  -1 
34  -4  -2 
Normal B6 spleen cells  B6  --  10  -4  -1 
FBL  --  8  -1  0 
B6/Thy-1.1 mice bearing disseminated  FBL-3 were cured in adoptive chemoimmunotherapy using 
CY plus 4.0 ×  107 FBL-specific, antigen-driven,  long term-cultured T cells (cultured 62 d) either 
alone or followed by IL-2 for 6 d (see Fig. 1 for details). 
* On  120 d  after  cell transfer,  mice  were  killed  and  spleen  cells were  placed  into culture  and 
stimulated  for 5 d with irradiated syngeneic B6 spleen cells, or irradiated FBL-3. 
* Effector populations  from culture were tested  untreated or after depletion  of donor T  cells with 
anti-Thy-l.2 + C' or depletion  of host T  cells with anti-Thy-l.1 + C', using reagents  previously 
described  (28). 
0 After culture with B6 or FBL, resultant  cells were tested  for cytolytic reactivity in a standard 4-h 
chromium-release  assay against the targets of FBL-3, B6 Con A blasts, and EL-4 (an antigenically 
distinct non-crossreacting  syngeneic B6 tumor). The cytotoxicity represents  the mean cytotoxicity 
from three experimental  mice. 
tions, since previous studies  in the FBL-3 system (using noncultured  spleen  cells 
from mice immune to FBL-3) have shown that CTL are of the Lyt-2  + phenotype 
and require  IL-2-producing Lyt-2- T  cells for proliferation  (27,  28). 
To test the potential  function of antigen-driven  long term-cultured  T  cells in 
vivo,  cultured  cells  were  used  for  the  therapy  of disseminated  FBL-3  as  an 
adjunct  to CY.  6  d  after  cell  transfer,  donor  T  cells  were  greatly  increased  in 
number.  The  proliferation  of donor T  cells in vivo was presumably in response 
to endogenous  production  of IL-2 by donor  helper/inducer  T  lymphocytes as 
described for in vitro-stimulated T  cells (29), and implies that the IL-2-producing 
Th  subset grown in vitro was able to survive adoptive cell transfer and function 
in vivo. 
The  demonstration  that antigen-driven  donor T  cells could distribute  widely 
and could be found in larger numbers in host ascites,  spleen,  and local-regional 
lymph  nodes  as  well  as  in  distant  lymph  nodes  was  surprising,  since  previous 
studies  (30-34)  have  shown  that  cultured  T  cells  traffic  abnormally  in  vivo, 
localize  poorly,  and  are  unable  to  migrate  into  peripheral  lymph  nodes.  The 
inability of cultured T  cells to traffic and to home in other studies is presumably 
multifactorial,  but included the major problem of being unable to proliferate  in 1108  CULTURED  T  CELLS  PROVIDE  IMMUNOLOGIC  MEMORY  IN  VIVO 
vivo (7,  14,  32,  35), a  problem seemingly circumvented by use of the culture 
systems described herein. 
The mechanism by which cultured T  cells gained entry in large numbers into 
mesenteric and axillary lymph nodes in this study is uncertain, because cultured 
T  cells  have  been  shown  (33,  36)  to  lack  receptors  for  adherence to  high 
endothelial venules (HEV); and adherence of iymphocytes to  HEV  is  the de- 
scribed first step  necessary for interendothelial cell  migration of iymphocytes 
into the parenchyma of lymph nodes. In the current study, donor T  cells may 
have reexpressed receptors for HEV in vivo and gained access to axillary lymph 
nodes mediated by specific adherence, or, alternatively, entry of cultured T  cells 
into  the  local-regional lymphatic compartment may have  occurred by  direct 
egress of i.p.-injected donor T cells into the collecting lymphatics in the omentum 
(reviewed in 34), and entry into distant axiilary lymph nodes may have occurred 
as  a  random  event  with  subsequent  rapid  proliferation  of donor  T  cells  in 
response to FBL-3 antigen within the lymph node. Regardless of the mechanisms 
allowing cell traffic, our results, in  comparison to previous studies using IL-2- 
dependent T  cells in vivo (14, 35), show that culture conditions play a major role 
in determining T  cell survival and distribution patterns in vivo. 
FBL-3  specific antigen-driven long  term-cultured T  cells proved to  be ex- 
tremely effective in tumor therapy. However, the mechanism of tumor eradica- 
tion was not determined. The cultured donor T  cell population contained both 
tumor-specific CTL  and  Th.  Thus,  it  is  possible  that either subset alone was 
responsible for therapeutic efficacy, or alternatively, that a collaborative inter- 
action between subsets in vivo was required. Previous studies using noncultured 
T  cells  from  immune  mice  in  the  same  therapy  model  established  that  the 
noncytolytic Lyt-2- Th subset can eradicate disseminated FBL-3 alone without 
the participation  of CTL  (27,  28),  presumably by secreting lymphokines and 
initiating a  delayed-type hypersensitivity reaction upon specific stimulation by 
tumor in  vivo.  A  similar antitumor effect might have been  mediated by  the 
cultured Th subset in the current experiment. However, since Th subsets vary 
greatly in requirements for in vitro growth (37),  it is as yet unknown whether 
the functional subset(s) of Th required for tumor eradication by this subset alone 
survive long-term culture. In the current studies, tumor-specific donor CTL may 
have  contributed  significantly to  therapeutic  outcome,  however,  it  is  highly 
unlikely that this subset, which presumably lacks the capacity to secrete IL-2 and 
proliferate in response to tumor stimulation, could mediate tumor elimination 
alone without IL-2 supplied either by collaborating Th or by exogenous admin- 
istration. 
The use of cloned T  cells in therapy might potentially provide evidence as to 
the mechanism of tumor eradication with antigen-driven T  cell lines. However, 
it  is  unknown  whether  disseminated  syngeneic  tumor  can  be  eradicated  by 
individual T  cell clones, or whether the progeny of a single cell can produce the 
requisite  lymphokines  in  the  proper  proportions  to  mediate  the  potentially 
complex set of interactions between donor and  host cells required for tumor 
eradication (28).  Moreover, the limited reactivity of a  single clone to a  single 
antigenic  moiety  might  prove  inadequate  for  therapy,  due  to  either  tumor 
heterogeneity or antigenic modulation. In the single published study (6) using T CHEEVER ET AL.  1109 
cell clones to  treat  FBL-3,  cloned T  cells capable of proliferating in  vitro  in 
response to FBL-3 had a demonstrable but limited effect in vivo, and cured no 
mice. 
The  administration  of exogenous  IL-2  for  six  consecutive  days  after  cell 
transfer increased the already rapid rate of proliferation of donor T  cells in vivo 
and resulted in a greatly increased number of donor T  cells surviving long term. 
Previous studies (14) using noncultured T  cells from mice immune to FBL-3, 
failed to show that  IL-2  could increase the rapid growth rate of noncultured 
antigen-stimulated T  cells in vivo. The ability of exogenous IL-2 to increase the 
rapid in vivo growth of cultured T  cells, in contrast to noncultured T  cells, may 
reflect an  inadequate  production  of endogenous IL-2  by cultured T  cells to 
support  maximal proliferation, or alternatively, that  T  cells activated in  vitro 
may be more responsive to exogenous IL-2 than cells activated in vivo. 
The expression of cell-mediated immunity in vivo is, in part, a  reflection of 
the number of immune T  cells present. Our results show that in vitro culture 
can be  used to  increase the number of antigen-reactive T  cells in  vivo.  The 
extent to which models for the therapy of antigenic murine leukemia can be 
generalized  to  man  is  uncertain.  However,  this  approach  may  prove  to  be 
applicable  to  several tumors already identified to be immunogenic, including 
HTLV ÷ ieukemias (39), idiotype- or clonotype-positive B and T cell malignancies 
(40), and tumors expressing unique membrane determinants such as might result 
from point mutation of an oncogene (41). In addition, this approach may prove 
applicable to the therapy of human viral, bacterial, fungal, and parasitic infectious 
diseases for which cellular immunity is limiting. 
Summary 
Mice bearing disseminated syngeneic FBL-3 leukemia were treated with cyclo- 
phosphamide plus long term-cultured T  cells immune to FBL-3. The cultured 
T  cells for therapy had been induced to grow in vitro for 62 d  by intermittent 
stimulation with irradiated FBL-3. At the time of therapy, such antigen-driven 
long term-cultured T  cells were greatly expanded in  number, proliferated in 
vitro in response to FBL-3, and were specifically cytotoxic. Following adoptive 
transfer, donor T  cells persisting in the host were identified and counted using 
donor and host mice congenic for the T  cell marker Thy-1. The results show 
that  antigen-driven  long  term-cultured  T  cells  proliferated  rapidly  in  vivo, 
distributed widely in host lymphoid organs, and were effective in tumor therapy. 
Moreover,  the  already rapid  in  vivo  growth  rate  of donor  T  cells could be 
augmented by administration of exogenous IL-2. 
When cured mice were examinedd 120 d after therapy, donor L3T4 ÷ T  cells 
and donor Lyt-2  ÷ T  cells could be found in large numbers in host ascites, spleen, 
and mesenteric and axillary lymph nodes. The persisting donor T  cells prolifer- 
ated in vitro, and became specifically cytotoxic in response to FBL-3, demonstrat- 
ing that antigen-driven long term-cultured T  cells can persist long term in vivo 
and provide immunologic memory. 
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